Please ensure Javascript is enabled for purposes of website accessibility

Here's Why AcelRx Pharmaceuticals, Inc. Jumped 16.5% on Monday

By Brian Orelli, PhD - Updated Sep 24, 2018 at 6:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors rush in ahead of an FDA advisory committee meeting.

What happened

Shares of AcelRx Pharmaceuticals (ACRX -3.96%) jumped 16.5% on Monday as investors buy shares ahead of a Food and Drug Administration advisory committee meeting to review its marketing application for Dsuvia, which is scheduled for Oct. 12.

So what

AcelRx is trying to get Dsuvia approved for the management of moderate-to-severe acute pain in medically supervised settings. The active ingredient, sufentanil, is approved for intravenous (IV) and epidural administration, but AcelRx developed a sublingual tablet that dissolves under the patient's tongue in hopes that it will avoid dosing errors associated with IV administration.

The company received a complete response letter -- the FDA's euphemism for a rejection letter -- last year in which the agency asked for more data from patients treated at the maximum dose, and also requested some changes in the instructions that accompany the drug on how to use it. Presumably, the FDA will ask the committee of outside experts about AcelRx's response to both topics when it meets next month.

October 2018 calendar

Image source: Getty Images.

While the meeting is scheduled for Oct. 12, investors should circle Oct. 10 on the calendar as well since two business days before the meeting, the FDA usually publicly posts the briefing documents it sent to the committee members. While the committee will make a recommendation about the approvability of Dsuvia, the FDA has the final say, so the reviewers' comments in the briefing documents are often more important than the meeting itself.

Now what

Traders who think in the short term often buy ahead of binary events like clinical trial results, FDA committee meetings, and FDA decisions, so investors should expect that AcelRx could continue to be volatile until the briefing documents are posted and the committee makes a recommendation at the meeting.

The FDA is scheduled to make a decision on or before Nov. 3, although that's just a goal set by the Prescription Drug User Fee Act (PDUFA) and not a hard deadline the agency absolutely has to meet. With less than a month between the meeting and the PDUFA date, investors should be prepared for a potential delayed decision.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AcelRx Pharmaceuticals, Inc. Stock Quote
AcelRx Pharmaceuticals, Inc.
ACRX
$0.22 (-3.96%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.